These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36124939)

  • 1. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
    Fischer SE; Vitale L; Agutu AL; Kavanagh MM
    J Health Polit Policy Law; 2024 Feb; 49(1):9-42. PubMed ID: 37522338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries.
    Chaudhary T; Chaudhary A
    J World Intellect Prop; 2021 Nov; 24(5-6):447-454. PubMed ID: 34908905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's yours is ours: waiving intellectual property protections for COVID-19 vaccines.
    Jecker NS; Atuire CA
    J Med Ethics; 2021 Sep; 47(9):595-598. PubMed ID: 34233956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Needle in a Haystack? Human Rights Framing at the World Trade Organization for Access to COVID-19 Vaccines.
    Perehudoff K; Qazilbash H; de Vries KF
    Health Hum Rights; 2022 Dec; 24(2):141-157. PubMed ID: 36579306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The COVID-19 Pandemic and the TRIPS Waiver: Patents and Flexibility.
    Lawson C; Rourke M
    J Law Med; 2022 Aug; 29(3):663-676. PubMed ID: 36056658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic.
    Lawson C
    J Law Med; 2023 Dec; 30(3):538-554. PubMed ID: 38332594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patent waiver on COVID vaccines is right and fair.
    Nature; 2021 May; 593(7860):478. PubMed ID: 34035532
    [No Abstract]   [Full Text] [Related]  

  • 14. Pandemics, intellectual property and 'our economy': A worldview analysis of Canada's role in compromising global access to COVID-19 vaccines.
    Brisbois B; Plamondon K; Walugembe D; Pereira RC; Edet C; Dixon J; Habibi R; Karamouzian M; Labonté R; Murthy S; Ravitsky V
    Glob Public Health; 2024 Jan; 19(1):2335360. PubMed ID: 38626321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and Global Distributive Justice: 'Health Diplomacy' of India and South Africa for the TRIPS waiver.
    Singh B; Chattu VK; Kaur J; Mol R; Gauttam P; Singh B
    J Asian Afr Stud; 2023 Aug; 58(5):747-765. PubMed ID: 37461426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap.
    Forman L; Jackson C; Fajber K
    Glob Public Health; 2023 Jan; 18(1):2256822. PubMed ID: 37715686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.
    Ballano VO
    Linacre Q; 2022 Feb; 89(1):47-63. PubMed ID: 35321490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 vaccine patent: a right without rationale.
    Althabhawi NM; Kashef Al-Ghetaa AA
    Med Humanit; 2023 Mar; 49(1):128-133. PubMed ID: 35523578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
    Mossoff A; Adalja A
    Inquiry; 2022; 59():469580221124819. PubMed ID: 36129280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.